Tumour vascularity is a significant prognostic factor for cervix carcinoma treated with radiotherapy: independence from tumour radiosensitivity
- PMID: 10496365
- PMCID: PMC2362853
- DOI: 10.1038/sj.bjc.6690700
Tumour vascularity is a significant prognostic factor for cervix carcinoma treated with radiotherapy: independence from tumour radiosensitivity
Abstract
The aim of the study was to investigate the relationship between intrinsic radiosensitivity and vascularity in carcinoma of the cervix given radiotherapy, and assess whether more refined prognostic information can be gained by combining the two parameters. A retrospective study was carried out on 74 patients with locally advanced carcinoma of the cervix. Formalin-fixed, paraffin-embedded tumour biopsies were stained with anti-factor VIII using immunohistochemistry. Vascularity was scored using the intra-tumour microvessel density (IMD), or 'hot-spot', technique. For the same patients, the measurement of intrinsic radiosensitivity (SF2) had been made previously on the same pretherapy samples. Patients were stratified by the median IMD and SF2 scores. Women with radioresistant and highly vascular tumours had poorer 5-year survival (P = 0.0005, P = 0.035 respectively) and local control (P = 0.012, P = 0.077 respectively) than those with radiosensitive and poorly vascular tumours. No significant correlation was seen between IMD and SF2. Multivariate analysis (including tumour stage and patient age) showed that only SF2 and IMD were significant prognostic factors for survival. Patients with both a radioresistant and highly vascular tumour had a 5-year survival level of 18% compared to 77% for those patients with a radiosensitive and poorly vascularized tumour. Tumour angiogenesis and cellular radiosensitivity are independent prognostic factors for cervix carcinoma treated with radiotherapy. Allowing for tumour radiosensitivity increases the prognostic significance of vascularity measurements in cervix tumours.
Similar articles
-
Vascular endothelial growth factor (VEGF) expression is a prognostic factor for radiotherapy outcome in advanced carcinoma of the cervix.Br J Cancer. 2000 Sep;83(5):620-5. doi: 10.1054/bjoc.2000.1319. Br J Cancer. 2000. PMID: 10944602 Free PMC article.
-
Influence of overall treatment time and radiobiological parameters on biologically effective doses in cervical cancer patients treated with radiation therapy alone.Acta Oncol. 2004;43(7):657-66. doi: 10.1080/02841860410018511. Acta Oncol. 2004. PMID: 15545186
-
Association between host tissue vascularity and the prognostically relevant tumor vascularity in human cervical cancer.Int J Oncol. 2001 Oct;19(4):827-32. Int J Oncol. 2001. PMID: 11562762
-
Tumor vascularity: a histological measure of angiogenesis and hypoxia.Cancer Res. 2001 Apr 1;61(7):2907-10. Cancer Res. 2001. PMID: 11306466
-
Relation of microvessel density with microvascular invasion, metastasis and prognosis in renal cell carcinoma.BJU Int. 2008 Mar;101(6):758-64. doi: 10.1111/j.1464-410X.2007.07318.x. Epub 2007 Dec 7. BJU Int. 2008. PMID: 18070177
Cited by
-
Predictive value of microvessel features for the clinical response to neoadjuvant chemotherapy in cervical squamous carcinoma and the associations with prognosis.Transl Cancer Res. 2021 Jan;10(1):162-173. doi: 10.21037/tcr-20-2741. Transl Cancer Res. 2021. PMID: 35116248 Free PMC article.
-
Validation of Potential Protein Markers Predicting Chemoradioresistance in Early Cervical Cancer by Immunohistochemistry.Front Oncol. 2021 Jul 19;11:665595. doi: 10.3389/fonc.2021.665595. eCollection 2021. Front Oncol. 2021. PMID: 34350111 Free PMC article.
-
Low Numbers of Vascular Vessels Correlate to Progression in Hormone-Naïve Prostate Carcinomas Undergoing Radical Prostatectomy.Cancers (Basel). 2019 Sep 12;11(9):1356. doi: 10.3390/cancers11091356. Cancers (Basel). 2019. PMID: 31547460 Free PMC article.
-
Contrast-enhanced ultrasonography of cervical carcinoma: perfusion pattern and relationship with tumour angiogenesis.Br J Radiol. 2016 Sep;89(1065):20150887. doi: 10.1259/bjr.20150887. Epub 2016 Jun 24. Br J Radiol. 2016. PMID: 27340932 Free PMC article.
-
Cediranib combined with carboplatin and paclitaxel in patients with metastatic or recurrent cervical cancer (CIRCCa): a randomised, double-blind, placebo-controlled phase 2 trial.Lancet Oncol. 2015 Nov;16(15):1515-1524. doi: 10.1016/S1470-2045(15)00220-X. Epub 2015 Oct 22. Lancet Oncol. 2015. PMID: 26474517 Free PMC article. Clinical Trial.
